心肌梗塞穆林模型中的 3D 生物打印贴片移植

Executive Industry Relevance

This protocol addresses a critical bottleneck in cardiac regeneration research: the reliable in vivo testing of 3D bioprinted therapeutic patches in murine myocardial infarction models. By reducing procedural variability and mortality associated with surgical transplantation, it enables more statistically robust preclinical evaluation of engineered tissues. This advancement supports de-risking of early-stage biologics and biomaterials by improving reproducibility in functional validation studies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables functional assessment of bioprinted patches in a disease-relevant ischemic microenvironment to validate mechanistic hypotheses of tissue engraftment and paracrine signaling.
• Operational Value: Standardizes surgical delivery of complex biologics, reducing inter-animal variability in engraftment efficiency.

Screening & Assay Development

• Scientific Value: Provides a reproducible platform for comparing patch formulations (e.g., cell types, hydrogel ratios) based on structural retention and integration metrics.
• Operational Value: Supports medium-throughput screening of biomaterial candidates by enabling consistent surgical delivery across study cohorts.

Translational & Preclinical Research

• Scientific Value: Facilitates longitudinal evaluation of patch-mediated ventricular remodeling and functional recovery in a clinically relevant model of ischemic injury.
• Operational Value: Enables powered studies with reduced attrition, improving feasibility of dose-response and timing optimization experiments.

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum by enabling standardized delivery of engineered tissues following target validation and prior to efficacy screening in disease models.

• Discovery Biology: Supports hypothesis testing regarding cell survival, engraftment, and bioactive factor secretion in infarcted myocardium.
• Screening: Enables quantitative comparison of patch designs through standardized surgical implantation and post-transplant monitoring.
• Analytics: Generates histopathological and functional readouts (e.g., infarct size, wall thickness) to rank patch performance.
• Translational Research: Bridges in vitro maturation metrics with in vivo functional outcomes to inform go/no-go decisions.
• Enterprise Reuse: Establishes a reusable surgical platform for evaluating diverse cardiac regenerative candidates across projects.

Operational & Enterprise Impact

• Scientific Value: Improves predictive confidence in preclinical models by reducing surgical confounding variables.
• Operational Value: Enhances reproducibility and scalability of complex tissue transplantation procedures.
• Strategic Value: Reduces biological noise in efficacy assessments, supporting clearer go/no-go decisions in early development.
• Portfolio Impact: Enables risk-adjusted prioritization of cardiac regeneration candidates based on more reliable preclinical data.

Implementation Considerations

• Requires expertise in murine cardiac surgery, anesthesia, and postoperative care.
• Depends on access to micro-suturing tools, ventilators, and stereomicroscopes for precise LAD ligation.
• Necessitates standardization of patch handling and positioning protocols across operators.
• Must account for variability in patch maturation timing based on cell source and hydrogel composition.
• Limited to acute and subacute injury models; not suited for chronic ischemia studies without model adaptation.

Biopharma FAQs